Avandia and Polycystic Ovary Syndrome in Diabetic Women
Polycystic ovary syndrome is an endocrine disorder and one of the causes of infertility in women of childbearing age. This is a hormone disorder which results in a condition when a woman's ovaries do not release an egg once a month as they should. Patients with this syndrome usually have characteristic symptoms of obesity, abnormal bleeding, severe acne, excessive hair growth or hair loss.
It is typical of women with polycystic ovary syndrome to be insulin resistant. Thus, this disease is concomitant to diabetes type 2. And one of the major features of polycystic ovary syndrome is hyperinsulinemia which in a compensatory manner accompanies the development of insulin resistance.
Patients with diabetes type 2 taking Avandia in the course of a glycemic therapy show evidence of beneficial effects that Avandia can produce on women with polycystic ovary syndrome. The point is that Avandia can reduce unhealthy high levels of insulin and thus it brings the blood glucose levels within the norm. And it is of pivotal significance that consequently women who are treated with Avandia can improve their fertility and regain their normal function.
As an effect of Avandia, ovulation may even occur in premenopausal women who do not have regular monthly periods. It can eventually lead to pregnancy. That is why it is important to take precautions and adequate means of contraception are usually recommended in this case.
Ovarian dysfunction may involve direct inhibition of ovarian steroidogenesis by glucocorticoids. Usually glucocorticoids are used to treat diseases caused by an overactive immune system, such as allergies, asthma, and sepsis. That is why if you are undergoing a clinical treatment with the help of glucocorticoids, you should discontinue Avandia-therapy. Unless you do it, such a combination can lead to total ovarian dysfunction.
Women with this syndrome should manage their lifestyle strictly, regularly determine their glucose levels and be careful about the medications they take. Avandia has proved to normalize ovulation in obese diabetic women afflicted with polycystic ovary syndrome. The studies demonstrate that success in treatment with the help of Avandia can be achieved within a span of three months. Besides, Avandia reduces testosterone levels in patients with polycystic ovary syndrome.
All in all, Avandia appears to be not only an anti-diabetic medicine, but also an effective adjuvant to treat a number of concomitant disorders, among which is polycystic ovary syndrome.